Researchers from Northwest A and F University in China built a microfluidics-based tissue that copies the liver's complex lobules, the organ's tiny structures that resemble wheels with spokes.
They did this with human cells from a liver and an aorta, the body's main artery.
In the lab, the engineered tissue had a metabolic rate that was closer to real-life levels than other liver models, and it successfully simulated how a real liver would react to various drug combinations.
When it does not work well, a person can suffer abdominal pain, swelling, nausea and other symptoms.
Complete liver failure can be life-threatening and can require a transplant, a procedure that currently depends on human donors.
To curtail this reliance and provide an improved model for predicting drugs' side effects, scientists have been engineering liver tissue in the lab. But so far, they have not achieved the complex architecture of the real thing.
The researchers conclude their approach could lead to the development of functional liver tissue for clinical applications and screening drugs for side effects and potentially harmful interactions.
The study was published in the journal Analytical Chemistry.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
